Abstract
Hydroxyurea (HU) is underutilized in sickle cell disease (SCD). Patient adherence with taking HU and with required drug monitoring is a provider perceived barrier to HU utilization.(1-4) To determine process issues that may contribute to these barriers we sought to: 1) describe how providers monitor and adjust HU dosing in children with SCD in clinical practice and 2) identify providers' methods of assessing HU adherence. A pilot-tested survey was emailed to American Society of Pediatric Hematology/Oncology (ASPHO) members. Descriptive statistics were performed. Thirty-one percent (n=350) of 1128 surveys were returned; 63% (220 of 350) of respondents provided care for children with SCD. Most providers (64.7%) follow labs monthly and almost half (41.9%) see patients monthly. The majority (61.9%) adjusted HU dosing using maximum tolerated dose commonly determined using ANC (27.9%), platelets (26.5%), and WBC count (11.2%). Adherence was primarily assessed using patient interview (84.2%), MCV (75.3%), and HbF levels (70.7%). The majority of providers perform monthly monitoring and assess HU adherence using unreliable methods. Determining optimal frequency of monitoring HU and more reliable methods of assessing adherence are essential to balancing safety and the elimination of barriers to promote HU utilization.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
